Soil Air-Water Properties in Catena of Sepopol Lowland

In the sequence of soil composed of black earths, deluvial soils, organic soils covered with a thin layer of mineral-organic deposit and moorsh soils, soil texture, bulk density, content of organic carbon and organic matter, total porosity, total and readily available water as well as resources of organic matter and water in 0-25 cm and 0-100 cm layers of the soil profile were studied. A catenal variabilities of organic matter content and physical-water properties were found. Physical properties and the contents of total and readily available water depended on soil texture, organic matter content and location in a relief. Total porosity, field water capacity and volume of macropores were positively correlated with organic matter content, and negatively with bulk density. Differences in studied properties between the pedons of black earths and deluvial soils were small, whereas these differences between deluvial and moorsh soils were distinct. In the development of water resources in the profiles of these soils, presence of organic subsoil with high retention capacity played the important role. The studied soils had unfavorable distribution of soil pores, resulting from a small volume of air pores

Angiocentric glioma from a perspective of A-B-C classification of epilepsy associated tumors

Angiocentric glioma (AG) is a newly-classified, very rare, WHO grade I central nervous system (CNS) lesion, occurring usually in children and young adults. Only 52 patients with AG have been reported so far, making it one of the rarest neuropathological entities. Hereby we present two new cases of AG in young subjects with detailed neuropathological investigations and a neuroradiological picture along with a brief summary of all already published literature reports of this tumor. Histopathological examination of the resected tissue from both cases revealed similar changes characteristic of AG. The tumors were composed of spindle-like, elongated cells, forming characteristic pseudorosettes around vessels and diffusively infiltrating surrounding tissue, trapping neurons between tumor cells. Noticeably, some neoplastic cells encrusting vessels extended far beyond the main tumor mass. Hypothetically, this may be responsible for the recurrence of the tumor even in the case of apparently total excision. In immunohistochemistry, AG cells were glial fibrillary acidic protein (GFAP) and vimentin positive, also exhibiting a strikingly significant epithelial membrane antigen (EMA) dot-like staining pattern. In one of the cases, electron microscopy revealed ependymal differentiation features such as microvilli and cilia. Taken together, all these data strongly confirm a dual astroglial-ependymal nature of the tumor. Follow up corroborates benign character of this neoplasm. Both AGs reported here were immunonegative for the product of the mutated IDH-1 gene what, according to our best knowledge, has never been reported so far. It may suggest that in their pathogenesis AGs differ from grade II astrocytomas, which in most cases harbor a mutation of IDH-1. Noteworthy, neuroimaging in our cases was relatively characteristic but not conclusive, therefore biopsy (at least) is mandatory. A newly proposed so called "A-B-C" classification of long-term epilepsy-associated tumors (LEATs) places AG in a category named ANET. The authors shortly review the A-B-C classification of LEATs

Interactions of tumour-derived micro(nano)vesicles with human gastric cancer cells

BACKGROUND: Tumour cells release membrane micro(nano)fragments called tumour-derived microvesicles (TMV) that are believed to play an important role in cancer progression. TMV suppress/modify antitumour response of the host, but there is also some evidence for their direct interaction with cancer cells. In cancer patients TMV are present in body fluid and tumour microenvironment. The present study aimed at characterization of whole types/subpopulations, but not only exosomes, of TMV from newly established gastric cancer cell line (called GC1415) and to define their interactions with autologous cells. METHODS: TMV were isolated from cell cultures supernatants by centrifugation at 50,000×g and their phenotype was determined by flow cytometry. The size of TMV was analysed by dynamic light scattering and nanoparticle tracking analysis, while morphology by transmission electron microscopy and atomic force microscopy. Interactions of TMV with cancer cells were visualized using fluorescence-activated cell sorter, confocal and atomic force microscopy, biological effects by xenografts in NOD SCID mice. RESULTS: Isolated TMV showed expression of CD44H, CD44v6 (hyaluronian receptors), CCR6 (chemokine receptor) and HER-2/neu molecules, exhibited different shapes and sizes (range 60–900 nm, highest frequency of particles with size range of 80–120 nm). TMV attached to autologous cancer cells within 2 h and then were internalized by them at 24 h. CD44H, CD44v6 and CCR6 molecules may play a role in attachment of TMV to cancer cells, while HER-2 associated with CD24 be involved in promoting cancer cells growth. Pre-exposure of cancer cells to TMV resulted in enhancement of tumour growth and cancer cell-induced angiogenesis in NOD SCID mice model. CONCLUSIONS: TMV interact directly with cancer cells serving as macro-messengers and molecular cargo transfer between gastric cancer cells resulting in enhancement of tumour growth. TMV should be considered in future as target of anticancer therapy

Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life

Background: Although research in this area remains sparse, raising a child with some genetic disorders has been shown to adversely impact maternal health and family quality of life. The aim of this study was to investigate such impacts in families with a child with the CDKL5 disorder, a newly recognised genetic disorder causing severe neurodevelopmental impairments and refractory epilepsy. Methods: Data were sourced from the International CDKL5 Disorder Database to which 192 families with a child with a pathogenic CDKL5 mutation had provided data by January 2016. The Short Form 12 Health Survey Version 2, yielding a Physical Component Summary and a Mental Component Summary score, was used to measure primary caregiver's wellbeing. The Beach Center Family Quality of Life Scale was used to measure family quality of life. Linear regression analyses were used to investigate relationships between child and family factors and the various subscale scores. Results: The median (range) age of the primary caregivers was 37.0 (24.6-63.7) years and of the children was 5.2 (0.2-34.1) years. The mean (SD) physical and mental component scores were 53.7 (8.6) and 41.9 (11.6), respectively. In mothers aged 25-54 years the mean mental but not the physical component score was lower than population norms. After covariate adjustment, caregivers with a tube-fed child had lower mean physical but higher mean mental component scores than those whose child fed orally (coefficient = -4.80 and 6.79; p = 0.009 and 0.012, respectively). Child sleep disturbances and financial hardship were negatively associated with the mental component score. The mean (SD) Beach Center Family Quality of Life score was 4.06 (0.66) and those who had used respite services had lower scores than those who had not across the subscales. Conclusions: Emotional wellbeing was considerably impaired in this caregiver population, and was particularly associated with increased severity of child sleep problems and family financial difficulties. Family quality of life was generally rated lowest in those using respite care extensively, suggesting that these families may be more burdened by daily caregiving

Foto-obrazy architektury: Fotografia jako medium referujące i projektujące architekturę

Praca recenzowana / peer-reviewed paperNiniejszy zbiór prac teoretycznych, fotoesejów i kronika studenckich konkursów fotograficznych organizowanych od 2008 roku na Wydziale Architektury i Sztuk Pięknych Krakowskiej Akademii im. Andrzeja Frycza Modrzewskiego, ma być zapisem refleksji związanych ze specyficzną, jak dotąd mało zbadaną a wszechobecną częścią teorii architektury, jaką jest fotografia. Jej szczególna odmiana ściśle związana ze sztuką budowania jest określana mianem fotografii architektonicznej, jednakże niniejsza monografia nie została tą definicją ograniczona.This book contains a selection of theoretical works and photo essays as well as a chronicle of photo competitions organised in the Faculty of Architecture and Fine Arts at Andrzej Frycz Modrzewski Krakow University since 2008, which is meant as the record of thoughts related to the specific, omnipresent though little examined so far, realm of the theory of architecture, i.e. photography. Its specific variant closely related to the building practice is called architectural photography. This monograph, however, is not restricted by means of the said definition and attempts at a slightly broader description of the phenomenon, reaching beyond its boundaries.Monografia powstała w ramach projektu badawczego nr WAiSP/DS/4/201

NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods

Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submit- Avenue, Silver Spring, Maryland 20993; 22Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia; 23Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovacˇ ic´ a 1, 10 000 Zagreb, Croatia; 24Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303; 25glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany; 26Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada; 27Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739–8530 Japan; 28ImmunoGen, 830 Winter Street, Waltham, Massachusetts 02451; 29Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31–126 Krakow, Poland; 30Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287; 31Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704; 32Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363–883 Korea (South); 33Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363–700, Korea (South); 34Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands; 35Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom; 36Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia; 37Proteomics, Central European Institute for Technology, Masaryk University, Kamenice 5, A26, 625 00 BRNO, Czech Republic; 38Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany; 39Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany; 40AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom; 41Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033; 42Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103; 43MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108; 44MSD, Molenstraat 110, 5342 CC Oss, The Netherlands; 45Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, 5–1 Higashiyama, Myodaiji, Okazaki 444–8787 Japan; 46Graduate School of Pharmaceutical Sciences, Nagoya City University, 3–1 Tanabe-dori, Mizuhoku, Nagoya 467–8603 Japan; 47Medical & Biological Laboratories Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464–0858 Japan; 48National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom; 49Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158–8501 Japan; 50New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938; 51New York University, 100 Washington Square East New York City, New York 10003; 52Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom; 53GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland; 54Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695; 55Pantheon, 201 College Road East Princeton, New Jersey 08540; 56Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810; 57Proteodynamics, ZI La Varenne 20–22 rue Henri et Gilberte Goudier 63200 RIOM, France; 58ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545; 59Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan; 60Children’s GMP LLC, St. Jude Children’s Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105; 61Sumitomo Bakelite Co., Ltd., 1–5 Muromati 1-Chome, Nishiku, Kobe, 651–2241 Japan; 62Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands; 63Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139; 64Department of Chemistry and Biochemistry, Texas Tech University, 2500 Broadway, Lubbock, Texas 79409; 65Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085; 66United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India; 67Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 68Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 69Department of Chemistry, University of California, One Shields Ave, Davis, California 95616; 70Horva´ th Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; 71Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary; 72Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711; 73Proteomics Core Facility, University of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden; 74Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden; 75Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden; 76Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany; 77Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; 78Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France; 79Natural and Medical Sciences Institute, University of Tu¨ bingen, Markwiesenstrae 55, 72770 Reutlingen, Germany; 80Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; 81Division of Bioanalytical Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands; 82Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757; 83Zoetis, 333 Portage St. Kalamazoo, Michigan 49007 Author’s Choice—Final version open access under the terms of the Creative Commons CC-BY license. Received July 24, 2019, and in revised form, August 26, 2019 Published, MCP Papers in Press, October 7, 2019, DOI 10.1074/mcp.RA119.001677 ER: NISTmAb Glycosylation Interlaboratory Study 12 Molecular & Cellular Proteomics 19.1 Downloaded from https://www.mcponline.org by guest on January 20, 2020 ted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide communityderived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods. Molecular & Cellular Proteomics 19: 11–30, 2020. DOI: 10.1074/mcp.RA119.001677.L

Chidren brought up in families with a disabled parent – pilot research

Problemy osób dorosłych z niepełnosprawnością dość rzadko podejmowane były przez pedagogikę specjalną, skupiającą się głównie na dzieciach i młodzieży. Niemniej jednak ostatnie lata przyniosły wzrost zainteresowania także tą grupą osób niepełnosprawnych. W swojej pracy badawczej zajęłam się wpływem niepełnosprawności rodzica na funkcjonowanie rodziny a w konsekwencji na wychowywane w niej potomstwo. Rodzice wytyczają a następnie utrwalają u swoich dzieci uznawany przez siebie system wartości. Podczas analizy przypadków szczególnie dokładnie przyjrzałam się wypełnianiu w rodzinach rencistów takich funkcji jak: ekonomiczna, opiekuńcza (zarówno w stosunku do dzieci jak i rodziców), socjalizacyjno – wychowawcza oraz emocjonalna.Problems of disabled adults have been described in special education literature relatively rarely as this realm of pedagogy focuses mostly on children and the youth. Nevertheless, for the past few years the interest in this group of the disabled has been increasing. In my research I aimed at the influence of a parent’s disability on a family’s effectiveness and, as a result, on children brought up in such a family. Parents define and stabilize their children’s value hierarchy. During the analysis of researched cases I focused especially on fulfilling economical, emotional, childcare, socializing and protective (towards children as well as towards parents) functions of pensioners’ families

Zmiany skórne w COVID-19 — opis przypadku

The paper presents a case of a 35-year-old woman with a history on the COVID-19. This disease was confirmed by PCR test. The woman’s medical history revelated endometriosis, cardiac arrhythmia and hypercholesterolemia. The first symptoms of COVID-19 were lower abdominal pain and diarrhoea, and in the next days — severe headache, muscle and joint pain, body weakness, dry cough, chest pains and many others. On the thirteenth day, the infection occurred to skin lesions on the face. The treatment applied resulted in clinical improvement.Przedstawiono przypadek 35-letniej kobiety z wywiadem dotyczącym COVID-19, potwierdzonym badaniem PCR. W wywiadzie ujawniono endometriozę, zaburzenia rytmu serca i hipercholesterolemię. Pierwszymi objawami COVID-19 były bole podbrzusza, biegunka, a następnie silny bol głowy, bole mięśniowo-stawowe, osłabienie, suchy kaszel i wiele innych. Zmiany skorne w obrębie twarzy w postaci plam rumieniowych pojawiły się w trzynastym dniu od zakażenia. W wyniku zastosowanej terapii uzyskano poprawę kliniczną.

Virtual reality in architecture - applications and benefits, part 2

Prezentowany tekst jest kontynuacją artykułu opublikowanego w Builder Science numer 2/2020 [1]. W materiale zostały opisane przypadki realnego zastosowania środowiska VR w kreowaniu wirtualnych przestrzeni. VR to skrót angielskiego Virtual Reality, w tłumaczeniu na język polski oznaczającego rzeczywistość wirtualną. Termin określa stereoskopową projekcję całkowicie sztucznego środowiska zbudowanego w czasie rzeczywistym, wśród której można się poruszać. Oba artykuły (poprzedni i obecny) są próbą odpowiedzi na pytanie: czy wirtualna rzeczywistość jest nam potrzebna? W pierwszym tekście autorzy zaprezentowali przykłady zastosowania wirtualnej rzeczywistości w branży budowlanej. Przeanalizowano efekty zastosowania tej technologii przez firmy deweloperskie oraz przedsiębiorstwo zajmujące się m.in. dystrybucją smart parkingów. Omówiono także aplikację House Customizer dającą możliwość tworzenia elementów trójwymiarowych w wirtualnej przestrzeni. W niniejszym artykule autorzy przedstawili zastosowanie wirtualnej rzeczywistości na przykładach z branży wyposażenia wnętrz oraz rozrywkowej. Prezentowane projekty różnią się stopniem zaawansowania użytej technologii, a także grupą docelową oraz celem, jaki miał zostać osiągnięty poprzez zastosowanie VR. Omawiane projekty zostały zrealizowane przez firmę Digital Wanderer (http://digitalwanderer.pl/), z którą współpracował jeden z autorów publikacji. Artykuł oparto na badaniach własnych, które przeprowadzono w trakcie współpracy z ww. firmą. W tekście wykorzystano obserwacje własne oraz wywiady przeprowadzone z klientami, inwestorami oraz uczestnikami wydarzeń, podczas których wykorzystano technologię VR.The presented text is a continuation of the article published in Builder Science number 2/2020 [1]. The text describes cases of real use of the VR build environment in creating virtual spaces. The abbreviation VR means the term Virtual Reality. This describes the stereoscopic projection of a completely artificial, virtual real-time built environment within which person can not only move but explore. Both articles (previous and present) are an attempt to answer the question: do we need Virtual Reality? In the first text, the authors presented examples of the use of VR in the construction industry. The effects of the use of this technology were analyzed by development companies, as well as by a company dealing, among others, with the distribution of Smart Parking lots. The House Customizer application was also discussed, giving the possibility to create three-dimensional elements in virtual space. In the present article, the authors presented the use of virtual reality on examples from the interior design and entertainment industries. The presented projects differ in the degree of advancement of the technology used, as well as the target group and the goal to be achieved through the use of VR. The projects discussed were carried out by Digital Wanderer studio (http://digitalwanderer.pl/), with which one of the authors of the publication collaborated. The article is based on own research carried out in cooperation with the above-mentioned company. In this text authors use their own observations, interviews with customers, investors and participants of events during which VR technology was used

Virtual reality in architecture – Applications and benefits

Do tematu wirtualnej rzeczywistości, zwanej też VR, wielu ludzi podchodzi sceptycznie. Ponadto stosunkowo niewiele osób, którym tematyka ta jest znana, przekonuje się do zastosowania nowego medium w codziennej pracy. Tekst jest próbą odpowiedzi na pytania: Jakie korzyści można czerpać z tej technologii? Czy wirtualna rzeczywistość jest nam potrzebna? Czego możemy się spodziewać po jej wejściu na rynek w przyszłości? Czy ta stosunkowo nowa technologia przetrwa próbę czasu i na stałe zagości w biurach architektonicznych? Zastosowanie VR nie ma ograniczeń, dlatego też wykorzystują ją różne dziedziny. W tekście opisano przypadki obrazujące realne zastosowania VR. Każdy z projektów jest inny ze względu na stopień zaawansowania użytej technologii. Przeanalizowane zostały projekty stworzone dla firm związanych z branżą budowlaną. Artykuł stworzono na podstawie badań własnych. Było to możliwe dzięki pracy w branży związanej z kreowaniem wirtualnej rzeczywistości. W jej trakcie przeprowadzono badania w postaci wywiadów z pracownikami firm oraz z inwestorami i osobami odwiedzającymi stanowiska z wirtualną rzeczywistością, np. podczas targów. Ponadto w badaniach wykorzystano obserwacje własne. Z badań wynika, że użycie wirtualnej rzeczywistości daje bardzo duże korzyści zarówno inwestorom, projektantom, jak i odbiorcom końcowym. Projektantom może skrócić czas pracy poprzez zintensyfikowanie procesu kreowania koncepcji. Pozwala na szybką weryfikację pomysłów i sprawdzenie ich poprawności. VR można rozpatrywać także jako świetne medium do komunikacji z klientem. Prezentacja towaru w wirtualnej rzeczywistości to także poprawa wyników sprzedaży oraz oszczędności (np. możliwość prezentowania wielu wariantów mieszkań bez konieczności fizycznego ich wznoszenia i aranżowania).Many people are skeptical about the subject of Virtual Reality. In addition, relatively a few people who know this subject are convinced to use this as a new medium in their daily work. This text is an attempt to answer questions: What benefits can be derived from this technology? Do we need Virtual Reality? What can we expect after it enters the market in the future? Will this relatively new technology stand the test of time and makes its place in architectural offices for good? The use of VR has no limits, which is why it is used by various fields. In this text there are descibed cases showing real VR applications. Each of the projects is different due to the advancement of the technology used. Projects created for companies related to the construction industry were analyzed. This article was created on the basis of own research. This was possible thanks to the work in the industry related in creating Virtual Reality. During this time period, research was conducted in the form of interviews with company employees as well as with investors and people visiting stands with Virtual Reality, e.g. during expos. In addition, own observations were also used in the study. Research shows that the use of Virtual Reality offers great benefits to investors, designers and end users. Designers can reduce their work time through a faster concept creation process. It allows you to quickly verify ideas and check their correctness. VR can also be considered as a great medium for communication with the client. Presentation of goods in virtual reality is also an improvement in sales results and savings (e.g. the ability to present many variants of flats without the need for physical construction and arrangement)